Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

SK biopharmaceuticals Co., Ltd.

에스케이바이오팜326030KOSPISector: Pharma & Biotech
₩85,0001.85%Market cap ₩6.66TAs of Sep 7, 2026 close · updated once daily
Market cap
₩6.66T
#87 in KOSPI
25.4x
Sector median 15.7x (profitable cos.)
8.34x
Sector median 1.59x
0.0%
Sector median 0.0%
A
Grade A67.3 ptsTop 16% of 2,522 graded stocksMethodology v2.0
Financial strength
77.6/100
Growth momentum
88.7/100
Price attractiveness
44.8/100
Shareholder Return
37.5/100

As of Sep 7, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,522 graded stocks and is currently in band A with a total score of 67.3 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩74,600High ₩140,700
Latest close
Price change by period
1W
2.60%
1M
0.40%
3M
3.50%
1Y
22.30%

As of the Sep 7, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

77.6/100
How much debt does it carry relative to equity?
45.0%
Sector median 51.6%
Sector lowhighTop 43.5% in sector
Can it cover what's due within a year?
231.4%
Sector median 191.7%
Sector lowhighTop 40.3% in sector
How much of revenue becomes profit?
28.9%
Sector median -2.4%
Sector lowhighTop 4.3% in sector
How much did it earn on its own capital?
32.8%
Sector median -4.5%
Sector lowhighTop 1.4% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

88.7/100
How much did revenue grow in a year?
29.1%
Sector median 6.4%
Sector lowhighTop 19.3% in sector
Has it grown steadily over three years?
42.1%
Sector median 4.9%
Sector lowhighTop 7.4% in sector
Did core profits grow in a year?
111.7%
Sector median 3.6%
Sector lowhighTop 12.2% in sector
Are core profits higher than three years ago?
255.6%
Sector median 3.5%
Sector lowhighTop 6.2% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

44.8/100
Is the price expensive relative to earnings?
25.4x
Sector median P/E of profitable peers 15.7x · 58% loss-making
Sector lowhighTop 26.9% in sector
Is the price expensive relative to book value?
8.34x
Sector median 1.59x
Sector lowhighBottom 16.4% in sector

Valuation uses the Sep 7, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 5 met · 3 not met · 1 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩267B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩176.3B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
33.3% → 25.7%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩176.3B vs ₩267B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
44.6% → 31.0%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
164.4% → 231.4%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Met
17.6% → 28.9%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.76x → 0.68x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026A

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →